MYUNGMOON Pharm co.,Ltd (017180.KS) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	199.8B	195.2B	186.4B	169.6B	152.1B
Cost of Revenue	85.4B	88.1B	81.5B	74.2B	74.0B
Gross Profit	114.4B	107.2B	105.0B	95.4B	78.1B
Operating Expenses
R&D Expense	6.4B	9.1B	2.1B	3.0B	1.7B
SG&A Expense	87.7B	76.7B	82.3B	72.5B	47.3B
General & Admin Expense	3.9B	5.4B	4.9B	4.2B	4.7B
Selling & Marketing Expense	54.9B	71.3B	77.4B	68.3B	42.7B
Other Expenses	20.0B	14.6B	18.7B	18.9B	22.6B
Total Operating Expenses	112.9B	100.4B	103.0B	94.4B	71.7B
Cost and Expenses	198.3B	188.4B	184.5B	168.6B	145.7B
Operating Income (EBIT)	1.5B	6.8B	1.9B	963.8M	6.4B
Non-Operating
Interest Income	29.5M	37.4M	108.6M	223.6M	150.8M
Interest Expense	4.7B	5.1B	5.4B	5.1B	3.7B
Net Interest Income	(4.7B)	(5.1B)	(5.2B)	(4.9B)	(3.6B)
Other Non-Op Income/Expense	(3.9B)	(4.2B)	(5.7B)	(5.7B)	(3.8B)
Non-Operating Income (excl Interest)	(585.5M)	—	321.5M	607.9M	47.1M
EBT (Pre-Tax Income)	(2.4B)	2.6B	(3.7B)	(4.8B)	2.7B
Income Tax Expense	203.8M	1.2B	45.4M	92.6M	(5.3B)
Bottom Line
Net Income	(1.7B)	1.9B	(3.0B)	(4.5B)	7.9B
Earnings from Cont. Ops	(2.6B)	1.4B	(3.8B)	(4.9B)	8.0B
Earnings from Discont. Ops	—	—	—	(268.00)	—
Bottom Line Net Income	(1.7B)	1.9B	(3.0B)	(4.5B)	7.9B
Per Share
Basic EPS	(₩60)	₩57	(₩91)	(₩134)	₩233
Diluted EPS	(₩60)	₩57	(₩91)	(₩134)	₩233
Revenue Per Share	₩5,978	₩5,751	₩5,568	₩5,035	₩4,500
Shares
Basic Shares Outstanding	33.4M	34.0M	33.5M	33.7M	33.8M
Diluted Shares Outstanding	33.4M	34.0M	33.5M	33.7M	33.8M
Profitability Metrics
EBITDA	4.6B	10.1B	5.7B	4.5B	10.6B
D&A	2.7B	3.3B	4.1B	4.2B	4.2B
EBIT	2.0B	6.8B	1.6B	355.8M	6.4B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026